Generate Biomedicines (NASDAQ:GENB – Get Free Report) and Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.
Earnings & Valuation
This table compares Generate Biomedicines and Eloxx Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Generate Biomedicines | $31.89 million | 39.84 | -$203.15 million | ($1.59) | -6.19 |
| Eloxx Pharmaceuticals | $6.36 million | 7.46 | -$5.99 million | ($1.54) | -7.62 |
Eloxx Pharmaceuticals has lower revenue, but higher earnings than Generate Biomedicines. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and target prices for Generate Biomedicines and Eloxx Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Generate Biomedicines | 1 | 1 | 6 | 0 | 2.62 |
| Eloxx Pharmaceuticals | 1 | 1 | 3 | 2 | 2.86 |
Generate Biomedicines presently has a consensus price target of $26.40, suggesting a potential upside of 168.29%. Eloxx Pharmaceuticals has a consensus price target of $37.33, suggesting a potential upside of 218.00%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than Generate Biomedicines.
Insider & Institutional Ownership
2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Generate Biomedicines and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Generate Biomedicines | -1,289.97% | -151.21% | -54.73% |
| Eloxx Pharmaceuticals | N/A | N/A | N/A |
Summary
Eloxx Pharmaceuticals beats Generate Biomedicines on 10 of the 13 factors compared between the two stocks.
About Generate Biomedicines
Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. Its research centered on compounds intended to help cells produce functional proteins when a genetic mutation prematurely stops protein production. The company’s lead investigational candidate, ELX-02, was designed to promote ribosomal readthrough of these premature stop signals. Eloxx studied the candidate for conditions including cystic fibrosis and nephropathic cystinosis in patients with relevant genetic mutations.
Receive News & Ratings for Generate Biomedicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generate Biomedicines and related companies with MarketBeat.com's FREE daily email newsletter.
